NeoGenomics, Inc.

Analysts expect NeoGenomics to turn profitable in 2026, supported by strong Q1 results that exceeded consensus on both revenue and EBITDA. Leerink Partners upgraded the stock to Outperform, raising its price target to $25, citing meaningful momentum in the oncology diagnostics segment as a key driver toward sustainable profitability.

Despite optimism, NeoGenomics has not yet achieved profitability over the last twelve months, and InvestingPro's Fair Value assessment suggests the stock is currently overvalued. The company's own narrative requires a $159.1 million earnings swing from -$99.2 million today to reach positive earnings by 2029, a highly uncertain target.

NeoGenomics' launch of the FDA-approved PTEN IHC CDx and Medicare MolDX coverage for PanTracer LBx demonstrate a credible push into integrated tissue and liquid biopsy offerings. Needham reiterated a Buy rating with a $15 price target, citing strong quarterly performance and the company's expanding oncology diagnostic capabilities.

While new companion diagnostic launches are promising, they do not eliminate key risks around intensifying competition, reimbursement uncertainty, and the company's history of losses. Analysts caution that new product adoption or pricing could easily fall short of the ambitious growth assumptions embedded in current forecasts.

NeoGenomics raised its 2026 revenue guidance after posting approximately 9% organic revenue growth in Q1, with the average analyst price target rising to $15.67, implying 11% upside. Wall Street Zen upgraded the stock from Hold to Buy, reflecting growing confidence in the company's revenue growth trajectory.

Reaching NeoGenomics' projected $982.4 million in revenue by 2029 requires 9.6% yearly growth sustained over several years — an ambitious target given competitive pressures in the medical laboratory market and the company's history of execution challenges. Technical indicators also signal a falling trend, raising questions about near-term momentum.